Sovereign Infrastructure & Strategic Healthcare Partnerships
Building regulated gene therapy capability inside national health systems rather than alongside them.
Triple Helix Science partners with sovereign wealth funds, national ministries of health, and institutional healthcare networks to establish domestic advanced therapy manufacturing, clinical trial capacity, and multi-jurisdictional translational infrastructure.
UAE Sovereign Partnership (Dubai & Abu Dhabi)
Building regulated gene therapy capability inside a national health system rather than alongside it.
The UAE has done something few jurisdictions have attempted: treated advanced therapy as national infrastructure to be built rather than as a foreign product to be imported once approved elsewhere. That position makes it possible to place manufacturing, regulatory engagement, and clinical delivery in the same country, under the same authorities, on the same timeline.
The intent is durable domestic capability — trained local staff, resident manufacturing, and protocols that continue to run without external dependency — rather than a service delivered from outside and withdrawn when a contract ends.
Domestic Advanced Therapy Infrastructure
Resident GMP manufacturing suites and specialized clinical delivery centers operating under unified national oversight.
Direct Regulatory Alignment
Active engagement with MOHAP and DHA authorities establishing clear multi-jurisdictional pathways for clinical trial delivery.
Durable Knowledge & Technology Transfer
Hands-on training for resident physicians, clinical fellows, and molecular biologists to ensure perpetual sovereign operational capability.
Sovereign Infrastructure Model
“Treated advanced therapy as national infrastructure to be built rather than as a foreign product to be imported once approved elsewhere.”
Multi-Jurisdictional Corporate & Clinical Architecture
Disciplined separation of operational entities, clinical governance, and nonprofit compassionate care.
Triple Helix Science operates across defined legal and clinical entities to ensure strict adherence to international GCP, GLP, and sovereign regulatory frameworks. Operating divisions across North America, Latin America, and the MENA region maintain localized compliance while adhering to a singular corporate quality standard.
Triple Helix Medicine
17 dedicated clinical specialty divisions delivering image-guided translational medicine and clinical protocols.
Triple Helix Veterinary
12 specialized veterinary divisions across companion animal longevity and equine musculoskeletal performance.
Triple Helix Lifestyle
Targeted cellular optimization and biomarker-anchored longevity medicine.
BioHelix NP Non-Profit
Establish a Sovereign Biotechnology Partnership
Engage directly with our executive office regarding national cleanroom joint ventures, sovereign clinical trial hubs, or technology licensing.